Application of Time-to-Event Methods in the Assessment of Safety in Clinical Trials Progress, Updates, Problems

William Jen Hoe Koh

May 9, 2013

Overview

- Marginal vs Conditional
- What is TMLE?
- Key Estimation procedure
- Some test simulations
- Hidden assumptions
- Hidden Statistical Properties

Brief Review: Time-to-event outcomes


$$S(t) = Pr(T > t) = 1 - F(t)$$

$$\lambda(t) = \lim_{\Delta t \to 0} \frac{\Pr[t \le T < t + \Delta t | T \ge t]}{\Delta t}$$

Event of Interest: Infection/AE at clinic visit

Right censored data: Non-ignorable missing data.

Discrete Failure Time (Zhang and Gilbert, 2010)



$$\lambda(t_j) = \Pr(T = t_j | T > t_{j-1})$$

T^{*}: "True" failure time (Unobserved due to discrete follow-up) $T = t_j$ if $T^* \in [t_{j-1}, t_j)$ with t_j for $j = 1, \dots, 10$. $\widetilde{T} = min(T, C)$: where *C* is our censoring time. $\Delta = I(T \leq C)$: Indicator of subject **not** being censored Objectives (Moore and van der Laan, 2009b)

- Estimate marginal treatment specific survival at a fixed end point
- Use covariates to gain efficiency
- Provide a consistent estimator in the presence of informative censoring

Approximate Scientific question: $Pr(T_1 > t_k) - Pr(T_0 > t_k)$

Event of Interest: First record of adverse event reported

Simplest analysis: Kaplan Meier Survival curves

Assumptions: Random censoring

Adjusted analysis: Cox-PH or Logistic regression (More assumptions)

RCT: Marginal or Conditional

Scientific question: $Pr(T > t_k | A = 1) - Pr(T > t_k | A = 0)$

Marginal

 $P(T > t | A = a) = S_0(t | A = a)$

Estimated probability of survival past time t for treatment a for the entire population.

Conditional

 $P(T > t | A = a, W) = S_0(t | A = a, W)$

Estimated probability of survival past time t for treatment a while holding W fixed.

What does TMLE estimate

Let $\Psi: \mathcal{M} \to \mathbb{R}$ is pathwise differentiable at any density $p_0 \in \mathcal{M}$


$$\underbrace{\Psi_{1}(p_{0})(t_{k}) = \overbrace{\mathsf{Pr}(T_{1} > t_{k})}^{Marginal} = E_{W}[\overbrace{S_{0}(t_{k}|A = 1, \mathbf{W})}^{Conditional}]}_{\Psi_{0}(p_{0})(t_{k}) = \mathsf{Pr}(T_{0} > t_{k}) = E_{W}[S_{0}(t_{k}|A = 0, \mathbf{W}])}_{\Psi_{AD}(p_{0})(t_{k}) = \Psi_{1}(p_{0})(t_{k}) - \Psi_{0}(p_{0})(t_{k})}$$

Consider the treatment group A = 1,

 $Pr(T_1 > t_k | \mathbf{W}) = S_0(t_k | A = 1, \mathbf{W})$: Probability of surviving beyond t_k when treatment is 1 given the covariates W.

 $Pr(T_1 > t_k) = E[S_0(t_k | A = 1, W)]$: Probability of surviving beyond t_k when treatment is 1 averaging over the covariates W.

Example: Random treatment assignment of 0.5



 $W \sim U(0.2, 1.2)$ $\lambda(t|A, W) = expit(-3 - A + W^2)I(t < 10) + I(t = 10)$

Idea behind TMLE (Van Der Laan, 2011)




Fig. 5.1 TMLE flow chart.

Likelihood representation for 1 observation

W: Covariates

A: Treatment

 (\widetilde{T}, Δ) : Time and event indicator $\overline{G}(t_{-}|A, \mathbf{W}) = \Pr(C \ge t|A, \mathbf{W})$ (Moore and van der Laan, 2009a) $S(t_k|A, W) = \prod_{t \leq t_k} [1 - \lambda(t|A, W)]$ $P_0(\mathcal{O}) = \Pr(\mathbf{W}, A, \widetilde{T}, \Delta) = \Pr(\widetilde{T}, \Delta | \mathbf{W}, A) \Pr(\mathbf{W}) \Pr(A | \mathbf{W})$ Q_{20} $=\left[\lambda(t_k|A,\mathbf{W})\prod_{t=1}^{t_k-1}(1-\lambda(t_k|A,\mathbf{W}))
ight]^{\delta}\left[\prod_{t=1}^{t_k}(1-\lambda(t_k|A,\mathbf{W}))
ight]^{1-\delta}$ $\bar{G}(t_{-}|A,\mathbf{W})^{\delta} \Pr(C = t_{k}|A,\mathbf{W})^{1-\delta} \Pr(\mathbf{W}) \Pr(A|\mathbf{W})$ Q_{10} **g**20 **g**10

Key Results for TMLE: Doubly robust

Q_0

 Q_{10} : Distribution of the baseline covariates

 Q_{20} : Conditional distribution of the hazard given treatment and baseline covariates

g0

g₁₀: Treatment mechanism

 g_{20} : Conditional distribution of the censoring distribution given treatment and baseline covariates

Either Q_0 or g_0 is correct, then TMLE is consistent

TMLE as Plug-in estimators

- 1. Estimate the $\hat{g}^0(A=1|W) = \frac{1}{n} \sum_{i=1}^n A_i$
- 2. Estimate the conditional probability of censoring $\overline{G}^0(t_-|A, W)$
- 3. Estimate the $\hat{\lambda}^0(t|A, W)$ via logistic regression

$$\operatorname{logit}[\hat{\lambda}^{0}(t|A,W)] = \sum_{i=1}^{K} \alpha_{i} I(t=i) + \beta_{A} A + \beta_{W} W$$

4. Update the above model using $\hat{\lambda}^0(t|A, W)$ by including the penalty $\epsilon = \{\epsilon_0, \epsilon_1\}$ and the "clever" covariate $\hat{h}^0(t, A, W) = \{\hat{h}_0, \hat{h}_1\}$

$$\begin{aligned} \operatorname{logit}[\hat{\lambda}^{1}(t|A,W)] &= \operatorname{logit}[\hat{\lambda}^{0}(t|A,W)] + \epsilon^{T}\hat{h}^{0}(t,A,W) \\ \widehat{h}_{i}(t,A,W) &= -\frac{I(A=i)I(t \leq t_{k})}{\hat{g}^{0}(A=i|W)\bar{G}^{0}(t_{-}|A,W)} \frac{\widehat{S}(t_{k}|A,W)}{\widehat{S}(t|A,W)} \end{aligned}$$

TMLE as Plug-in estimators continued

5. Use current estimate of $\widehat{\lambda}^1(t|A,W)$ to update $\widehat{h}^1(t,A,W)$


$$\widehat{S}(t_k|A,W) = \prod_{t \leq t_k} [1 - \widehat{\lambda}^1(t|A,W)]$$

6. Iterate 4 & 5 until $\widehat{\epsilon} \to 0$


7. Plug-in final estimate of $\widehat{S}_i^*(t_k|A=i,W)$ for i=0,1

$$egin{aligned} \widehat{\Psi}_1(p_0)(t_k) &= rac{1}{n}\sum_{i=1}^n \widehat{S}^*(t_k|A=1,W_i) \ \widehat{\Psi}_0(p_0)(t_k) &= rac{1}{n}\sum_{i=1}^n \widehat{S}^*(t_k|A=0,W_i) \end{aligned}$$

Test simulations with no covariates



Test Simulations for weak covariates



Elixir of life

Time of record of Adverse Event

Simulations $W \sim U(0.2, 1.2); A \sim Bin(0, \frac{1}{2})$ $\lambda(t|A, W) = expit(-3 - A + W^2)I(t < 10) + I(t = 10)$

Problem

Survival function never increases over time.



Acknowledgements: Taken from bartsblackboard.com

Next steps

Compute the variance/Bootstrap

Rerun simulations

Fill in the gaps in the paper

Extensions

References

- Moore, K. and van der Laan, M. (2009a). Increasing power in randomized trials with right censored outcomes through covariate adjustment. *Journal of biopharmaceutical statistics*, 19(6):1099–1131.
- Moore, K. L. and van der Laan, M. J. (2009b). Application of time-to-event methods in the assessment of safety in clinical trials (chapter 20). In Peace, K. E., editor, *Design and Analysis of Clinical Trials with Time-to-Event Endpoints*, pages 455–482. Chapman and Hall/CRC; Biostatistics Series.
- Stitelman, O. and van der Laan, M. (2010). Collaborative targeted maximum likelihood for time to event data. *The international journal of biostatistics*, 6(1):Article–21.
- Van Der Laan, M. (2011). Targeted Learning: Causal Inference for Observational and Experimental Data. Springer.
- Zhang, M. and Gilbert, P. B. (2010). Increasing the efficiency of prevention trials by incorporating baseline covariates. *Statistical communications in infectious diseases*, 2(1).

Thinking in counterfactuals



You take the red pill - you stay in Wonderland and I show you how deep the rabbit hole goes. You take the blue pill - the story ends, you wake up in your bed and believe whatever you want to believe.

Morpheus, The Matrix

Hidden Assumptions: Thinking in counterfactuals

For an individual in the placebo arm...

$$\begin{split} IC^*_{0t_k}(\rho_O) &= \sum_{t \leq t_k} [I(\tilde{T} = t, \Delta = 1) - I(\tilde{T} \geq t)\lambda(t|A = 0, W)]h_0(t, A, W) \\ &+ \frac{S_0(t_k|A = 0, W) - \Psi_0(\rho_O)(t_k)}{2} \end{split}$$

$$h_i(t,A,W) = -\frac{I(A=i)}{g(1)\overline{G}(t_-|A,W)} \frac{S(t_k|A,W)}{S(t|A,W)} I(t \le t_k)$$

Key assumptions 1: Coarsening at random

Definition of CAR (Stitelman and van der Laan, 2010)

Coarsened data structures are data structures where the full data is not observed.

"Coarsening mechanism" is only a function of the full data, i.e. the data in which you would have seen all counterfactuals, through the observed data

Implications

 $dP_0(O) = Q_0(O)g_0(O|X)$

 Q_0 is the density associated with full data

 g_0 contains the censoring and treatment mechanism.

 \mathcal{M} is the set of possible probability distribution of \mathcal{O} with probability distribution $P_0 \in \mathcal{M}$ where \mathcal{M} is dominated by common measure μ . Hence, density $p = \frac{dP_0}{d\mu}$

 O_1, \cdots, O_n are *n* i.i.d realizations of \mathcal{O} .

 O_1, \dots, O_n can be represented by the empirical probability distribution P_n placing mass 1/n on each of the *n* observations.

Statistical properties

TMLE uses solves the efficient Influence curve.

IDEA: If we can linearize our estimator

Linearity of estimator

An estimator $\psi_{\textit{n}}$ is an asymptotically linear estimator of a parameter ψ if

$$\psi_n - \psi = \frac{1}{n} \sum_{i=1}^n IC_P(O_i) + o_P\left(\frac{1}{\sqrt{n}}\right)$$

where the influence curve $IC_P(O)$ has expectation 0 and finite variance i.e. $IC_P(O) \in L^2_0(P)$ and moreover this should hold for all $P \in \mathcal{M}$.

Efficient Influence curve

Asymptotic Distribution

The asymptotic distribution (via linearity of the influence curve)

$$\sqrt{n}\left(\hat{\psi}^*(t_k)-\Psi(p_0)(t_k)\right)\to N(0,\sigma^2)$$

Estimate σ^2 by empirical variance

$$\hat{\sigma}^2 = \frac{1}{n} \sum_{i=1}^n IC_P(O_i)^2$$

Implications

Compute Wald-like confidence intervals $\hat{\psi}^*(t_k) \pm 1.96 rac{\hat{\sigma}^2}{\sqrt{n}}$